NCI Renews Support for Major Thyroid-Cancer Research Effort at Ohio State  

Share this news item:

Contact Us

For media inquiries:
614-293-3737

To find a doctor, get a referral or for information on a clinical trial:
614-293-5066
or 800-293-5066

Search for a clinical trial

Posted: 9/3/2013

<p>Matthew D. Ringel, MD<br /></p>

Matthew D. Ringel, MD

 
COLUMBUS, Ohio – The National Cancer Institute (NCI) has awarded a five-year, $11.3 million grant to a team of researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to further their studies on thyroid cancer.
 
Principal investigator Matthew D. Ringel, MD, professor of medicine and a member of the OSUCCC – James Molecular Biology and Cancer Genetics (MBCG) Program, leads the NCI Program Project Grant (CA124570). The new grant is a continuation of a study that ran from 2008 through 2013 entitled “Genetic and Signaling Pathways in Epithelial Thyroid Cancer.”
 
The study has four integrated projects:
  • “Genes in the Predisposition to Papillary Thyroid Carcinoma,” led by Albert de la Chapelle, MD, PhD, co-leader of the OSUCCC – James  MBCG Program;
  • “Genetic Alterations That Initiate Follicular Thyroid Carcinogenesis,” led by Charis Eng, MD, PhD, at the Cleveland Clinic, and co-led by Lawrence Kirschner, MD, PhD, of the OSUCCC-James MBCG Program;
  • “Selective Modulation of Thyroidal Radioiodine Accumulation,” led by Sissy Jhiang, PhD, of the OSUCCC – James MBCG Program;
  • “P21-Activated Kinase in Thyroid Cancer” led by Ringel, a member of the OSUCCC-James MBCG Program and director of the Division of Endocrinology, Diabetes and Metabolism at Ohio State. 
In addition, the Program Project Grant funds three shared-resource cores:
  • “Integrated Clinical Information and Pathology Sample Repository,” led by John Phay, MD, of Ohio State’s Division of Surgical Oncology, and by Rebecca Nagy, CGC, of Ohio State’s Division of Human Genetics;
  • “Mouse Imaging and Pathology,” led by Kirschner;
  • “Biostatistics and Data Integration,” led by Soledad Fernandez, PhD, of Ohio State’s Department of Biomedical Informatics.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.
 
###
 
 
Contact: Darrell E. Ward, Wexner Medical Center Public Affairs and Media Relations,
614-293-3737, or Darrell.Ward@osumc.edu
 


Tags: Clinical/Translational Research; Thyroid Cancer

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu